Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients is a phase 1/2, interventional study registered as NCT03190941 by National Cancer Institute (NCI), with a registry enrolment figure of 110 participants, started 2017-09-21 and due to reach its primary completion in 2027-06-29. Interventions recorded: Cyclophosphamide; Fludarabine; Anti-KRAS G12V mTCR PBL; Aldesleukin. Conditions listed: Pancreatic Cancer; Gastric Cancer; Gastrointestinal Cancer; Colon Cancer; Rectal Cancer. Primary outcome: Response rate; Frequency and severity of treatment-related adverse events. Pancreatic eligibility wording from the registry: "* Patients with pancreatic cancer must have received gemcitabine, 5FU, and oxaliplatin (or similar agents), or have contraindications to receiving those medications". Sites: United States. No results are recorded here; the registry entry is the source.